QUOTE AND NEWS
Benzinga  Sep 12  Comment 
In a report published Friday, Mizuho Securities USA analyst Peter Lawson initiated coverage on NewLink Genetics Corp (NASDAQ: NLNK) with a Buy rating and $50.00 price target. In the report, Mizuho Securities USA noted, “We are initiating...
DailyFinance  Sep 4  Comment 
AMES, IA -- (Marketwired) -- 09/04/14 -- NewLink Genetics Corporation (NASDAQ: NLNK) today announced that the United States Food and Drug Administration (FDA) has given permission for the Company to proceed to Phase 1 clinical trials with their...
StreetInsider.com  Aug 21  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/WHO+Offers+Update+on+Ebola+Outbreak+for+Aug.+17+-+18+%28TKMR%29+%28BCRX%29+%28NLNK%29/9773658.html for the full story.
SeekingAlpha  Aug 15  Comment 
By Ramon Flick: Newlink Genetics Corporation (NASDAQ:NLNK) is going beyond cancer and receives $1.0 million for Investigational New Drug (IND)-enabling studies for their Ebolavirus countermeasure. The United States Defense Threat Reduction Agency...
StreetInsider.com  Aug 14  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/FDA+Warns+Against+Fake+Ebola+Treatment+Products+%28TKMR%29+%28BCRX%29+%28NLNK%29/9755592.html for the full story.
TheStreet.com  Aug 14  Comment 
NEW YORK (TheStreet) -- NewLink Genetics shares are up 9.9% to $25.75 on Thursday after the drug developer announced that it is prepared to begin the initial round of human testing for an Ebola vaccine. The company has not set up a timetable to...
Clusterstock  Aug 12  Comment 
The Ebola trade is having a rough day.  Tekmira Pharmaceuticals, which has had a volatile three days, was down 18% on Tuesday after gains of 45% and 15% on Friday and Monday, respectively. Friday's pop in Tekmira followed a Thursday evening...
DailyFinance  Aug 5  Comment 
AMES, IA -- (Marketwired) -- 08/05/14 -- NewLink Genetics Corporation (NASDAQ: NLNK) today reported consolidated financial results for the second quarter of 2014 and progress in its development programs. "We continue to expand our clinical...
DailyFinance  Aug 5  Comment 
AMES, IA -- (Marketwired) -- 08/05/14 -- NewLink Genetics Corporation (NASDAQ: NLNK), through its wholly owned subsidiary, BioProtection Systems Corporation (BPS), today announced a letter contract with the United States Defense Threat Reduction...
DailyFinance  Jul 28  Comment 
AMES, IA -- (Marketwired) -- 07/28/14 -- NewLink Genetics Corporation (NASDAQ: NLNK), today announced that an oral presentation on efficacy of influenza vaccines modified with the alpha-Gal carbohydrate will be given at the XVIth International...




 
TOP CONTRIBUTORS

NewLink Genetics (NASDAQ:NLNK) is a biopharmaceutical which develops drugs to help treat cancer patients.[1] The company focuses on immunotherapy - or treatment by causing the immune system to either act or cease to act. In other words, NewLink Genetics attempts to encourage the patients immune system to combat the cancerous cells rather than attempting to kill the cells directly.[2] NewLink Genetics revenues are dependent on the discovery and FDA approval of its therapies.

Business Overview

For the full year 2010, NewLink generated $2.1M in grant revenue. This was an over 100% increase from the $.9M in 2009. Since the company spends heavily on research and development, it still reported a net loss for 2010 of $16.6M. This compares to a net loss of $10.2M in 2009. [3]

New Updates

The company's initial public offering of stock on the NASDAQ occurred on November 10, 2011. The company offered 6.2M shares each for $7. The company had already planned to sell 5.5M shares. However, since they priced below the $10-$12 range, they increased shares. The deal raised a total of $43M. The lead mangers of the deal were Stifel Financial (SF) and Canaccord Genuity.[4]

Trends & Forces

Dependence on FDA approval

As of its IPO, NewLink did not have any FDA approved drugs. It's quite clear that without a completed drug, the company will be unable to produce substantial operating revenue. As a result, the company's performance is limited to actions from the FDA. Furthermore, since NewLink is in the process of developing new, untested treatments, there is no clear guidance for the likelihood of approval or the likelihood that physicians will adopt new treatments.[5]

  1. NLNK S-1/A 2011 PROSPECTUS SUMMARY "Overview p. 1
  2. American Cancer Society - Find Support and Treatment "Immunotherapy"
  3. NLNK S-1/A 2011 PROSPECTUS SUMMARY "Selected Financial Data p. 51
  4. Renaissance Capital - IPO Home "NewLink Genetics prices IPO at $7, below the range" 11 Nov 2011
  5. NLNK S-1/A 2011 PROSPECTUS SUMMARY "Risk Factors" pp. 11-15
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki